Actionable news
0
All posts from Actionable news
Actionable news in ARWR: Arrowhead Research Corporation,

Company Update (NASDAQ:ARWR): Arrowhead Pharmaceuticals Inc Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it has dosed the first patient in the multiple ascending dose (MAD) portion of its ongoing Phase 1/2 study of ARC-521, the company’s second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. To date 24 healthy volunteers have been treated in the study, and the drug safety committee (DSC) approved initiation of the MAD after a planned review of safety data from cohort 3 of the healthy volunteer portion of the study. The MAD is designed to evaluate the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV.

Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead said, “The innovative design for the first-in-man study of ARC-521 is intended to get to multiple dose data in patients rapidly. Arrowhead’s...


More